A CU Anschutz Cancer Center member is recruiting women with advanced breast cancer for a worldwide clinical trial investigating a pair of new therapies.

Prostate cancer is the most common cancer among U.S. men, and rates vary among different groups. When to get screened depends on who’s getting screened.

A personalized melanoma vaccine developed by Moderna and Merck, used with Keytruda, greatly reduced melanoma recurrence risk in trials.

Primarily used to treat breast cancer and prostate cancer hormone therapy is an effective treatment method.

FDA announced approval of daraxonrasib, a new targeted treatment for pancreatic cancer. CU Anschutz physician Dr. Wells Messersmith served as principal investigator.

Breakthrough drug nearly doubles survival with advanced pancreatic cancer – an oncologist explains how daraxonrasib overcame an ‘undruggable’ disease

Doctors have learned how to harness the immune system to seek out and destroy cancer cells in a targeted fashion that does not destroy healthy cells.

Doctors have learned how to harness the immune system to seek out and destroy cancer cells in a targeted fashion that does not destroy healthy cells.

Urs Weber, MD, explains how multidisciplinary teams streamline biomarker testing and improve treatment planning in thoracic oncology.

Fecci began by noting the importance of the IDH inhibitor class, including vorasidenib (Voranigo).

A new approach to genetic testing for patients with prostate cancer is leading to an increase in testing for those who qualify.